Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease
Authors:
- Lorcan P.A. McGarveyLMLorcan P.A. McGarvey
- 21 January 2017
- journal article
- review article
- Published by S. Karger AG in Respiration
- Vol. 93 (3) , 153-161
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are prevalent conditions, and despite recent advances and multiple available therapies and interventions, there remains a significant unmet clinical need. In recent years, it has become clear that there is both significant heterogeneity within each of these conditions and additionally significant overlap in many of the clinical and inflammatory features. In parallel, useful clinical and immunological biomarkers which inform about prognosis and response to therapy have emerged in both asthma and COPD. These biomarkers will allow both better targeting of existing treatments and the identification of those patients who will respond to novel therapies which are now becoming available. Biomarkers will also facilitate the identification of novel therapeutic targets for future development. Delivery of precision medicine in airways disease is now feasible and is a core component of a personalised healthcare delivery in asthma and COPD.Keywords
This publication has 57 references indexed in Scilit:
- Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment?Cough, 2013
- Phenotyping airways disease: an A to E approachClinical & Experimental Allergy, 2012
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Misuse of Respiratory Inhalers in Hospitalized Patients with Asthma or COPDJournal of General Internal Medicine, 2011
- Symptom variability in patients with severe COPD: a pan-European cross-sectional studyEuropean Respiratory Journal, 2010
- Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- Severe asthma treatment: need for characterising patientsThe Lancet, 2005
- Predictors of therapy resistant asthma: outcome of a systematic evaluation protocolThorax, 2003